Across a 140-day span, the pace is roughly 0.6 stories per week. The busiest single day carried 2. regulation accounts for 7 of the 12 tracked stories, while 2 other categories carry the remainder. Of the tracked stories, 2 of 12 also mention #WeCount report, the most common co-covered peer.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Food and Drug Administration (FDA)
Across a 140-day span, the pace is roughly 0.6 stories per week. The busiest single day carried 2. regulation accounts for 7 of the 12 tracked stories, while 2 other categories carry the remainder. Of the tracked stories, 2 of 12 also mention #WeCount report, the most common co-covered peer. Each carries 15.8 original sources on average. Negative sentiment appears in 33% of the tracked stories. Food and Drug Administration (FDA) appears in 12 tracked Cross-Sector stories published from February 26, 2026 through July 15, 2026.
Stories tracked
12
Per week
0.6
Negative
33%
Sources per story
15.8
Computed from the 12 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Food and Drug Administration (FDA). Shared-story counts are live from our verified record — not editorial picks.
A seven-day administrative hearing is held in Arlington, Virginia, debating whether marijuana has a 'currently accepted medical use' without MMJ's testimony or evidence.
DEA Excludes MMJ from Rescheduling Hearing
The DEA denies MMJ International Holdings' request to participate in the upcoming administrative hearing, asserting that its evidence raises only questions of law.
Federal Appeals Court Bans Mailing Mifepristone
A federal appeals court made it illegal to mail mifepristone, a key medication abortion pill, threatening telehealth access.
Supreme Court Issues Stay on Mifepristone Ban
The Supreme Court stayed the appeals court ruling, allowing mailing to continue while the legal challenge proceeds.
Legal Challenges
Expected filing of lawsuits by environmental groups to block the relaxation of standards.
EPA Rollback Proposal
The EPA announces moves to weaken the previously established pollution limits.
Industry Consensus
Scientific American and other major outlets report a definitive decline in global animal experiment volumes.
Industry Petitions
Medical tech groups and the FDA raise alarms about potential device shortages due to facility closures.
Major CRO Pivot
Leading Contract Research Organizations announce multi-million dollar investments in digital twin and OOC labs.
Strict Standards Finalized
EPA issues a rule requiring a 90% reduction in EtO emissions from sterilization plants.
FDA Guidance on NAMs
The FDA issues initial framework for the submission of data derived from microphysiological systems.
FDA Modernization Act 2.0
President Biden signs legislation ending the mandate for animal testing for new drug applications.
Supreme Court Overturns Roe v. Wade in Dobbs Decision
The landmark ruling eliminated the constitutional right to abortion, allowing states to enact bans.
Stories mentioning Food and Drug Administration (FDA) 12
The CDC's health alert on a cyclosporiasis outbreak with 5,100 suspected cases presents urgent needs in the biotech sector for rapid diagnostics, antiparasitic drug development, and food safety technologies. The parasite Cyclospora cayetanensis, with its long incubation period, challenges traditional detection methods, while treatment relies on a decades-old antibiotic. Innovators could capitalize on multiplex PCR panels and next-generation sequencing for outbreak tracking.
MMJ International Holdings alleges the DEA violated administrative law by excluding it from marijuana rescheduling hearings, despite spending $10 million on FDA-pathway development. The exclusion raises due process and APA concerns that could imperil the final rule.
Despite state bans, U.S. abortions nearly doubled, fueled by telehealth pill delivery across state lines. This exposes legal tensions between state authority, FDA preemption, and 19th-century obscenity statutes.
U.S. abortions nearly doubled between 2021 and 2025, with medication abortion now 63% of the total. Telehealth delivery has enabled this surge, though misoprostol-only use raises clinical concerns.
The sudden closure of a primary peptide supplier has sent shockwaves through the biotech research community, significantly reducing the availability of high-purity compounds. Nova Life Peptides warns that this contraction will likely lead to increased costs and delayed timelines for preclinical studies.
The Environmental Protection Agency has proposed a relaxation of pollution standards for chemicals used in medical equipment sterilization, specifically targeting Ethylene Oxide (EtO). This move attempts to balance carcinogenic health risks against the critical need to maintain the national medical device supply chain.
A nationwide recall has been issued for a wellness supplement following the discovery of sildenafil, the active ingredient in the prescription drug Viagra. The presence of this undeclared pharmaceutical poses severe health risks, particularly through potentially fatal interactions with common heart medications.
The pharmaceutical industry faces renewed scrutiny over direct-to-consumer (DTC) advertising, a practice unique to the U.S. and New Zealand. As healthcare costs rise, regulators are weighing the educational benefits of these ads against their role in driving up prescription volumes and drug prices.
A renewed public debate over Direct-to-Consumer Advertising (DTCA) is challenging the pharmaceutical industry's marketing status quo in the United States. As healthcare costs escalate, regulators and lawmakers are weighing the educational benefits of patient outreach against the risks of over-prescription and inflated drug prices.
The pharmaceutical industry is undergoing a paradigm shift as regulatory changes and technological breakthroughs reduce reliance on animal models. With the FDA Modernization Act 2.0 paving the way, human-on-a-chip and AI-driven simulations are emerging as more predictive alternatives for drug safety and efficacy.
The long-standing paradigm of animal experimentation is facing an unprecedented decline as regulatory frameworks and advanced biotechnologies converge. Following the landmark FDA Modernization Act 2.0, the industry is pivoting toward 'New Approach Methodologies' that promise higher human predictive value and lower development costs.
The U.S. Food and Drug Administration is implementing a performance-based bonus structure to reward staffers who complete drug reviews ahead of schedule. This initiative aims to accelerate the therapeutic pipeline but has sparked immediate debate over the potential impact on safety standards and regulatory rigor.
